P. Ravenstijn

发表

Design and conduct considerations for studies in patients with impaired renal function

M. Chetty, P. Ravenstijn, Pooja Manchandani, 2021, Clinical and translational science.

18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446

Mark E. Schmidt, G. Bormans, K. Van Laere, 2018, The Journal of Nuclear Medicine.

Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia

S. Gopal, A. Savitz, A. Vermeulen, 2015, Current medical research and opinion.

A physiologically based pharmacokinetic modeling approach to predict drug–drug interactions between domperidone and inhibitors of CYP3A4

J. Snoeys, P. Ravenstijn, C. Sensenhauser, 2016, Biopharmaceutics & drug disposition.

Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants

M. Furey, G. Triana-Baltzer, A. Bhattacharya, 2018, Journal of psychopharmacology.

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: A phase‐1, single‐dose, randomized, open‐label study

S. Gopal, B. Remmerie, M. De Meulder, 2016, Journal of clinical pharmacology.

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

W. Fleischhacker, S. Gopal, A. Savitz, 2016, The international journal of neuropsychopharmacology.

The Role of the Blood-Brain Barrier

M. Danhof, P. Ravenstijn, 2009 .

Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open‐Label, Crossover, Drug‐Drug Interaction Studies

J. Smit, D. Upmalis, R. Terlinden, 2010, Pharmacotherapy.

Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling

E. D. Lange, D. Groenendaal, P. Ravenstijn, 2005, The AAPS Journal.

Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial

W. Drevets, J. V. van Gerven, M. D. de Kam, 2020, Journal of psychopharmacology.

Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration

M. Chetty, P. Ravenstijn, Pooja Manchandani, 2020, Clinical pharmacology and therapeutics.

Animal Models as a Tool in Systems Pharmacology Research on Parkinson's Disease

M. Danhof, P. Ravenstijn, 2009 .

Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [18F]JNJ-64413739 PET and MRA-driven image derived input function

K. Van Laere, M. Koole, J. D. de Hoon, 2021, Scientific Reports.

Translational Model‐Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ‐54175446, a P2X7 Receptor Antagonist

Honghui Zhou, P. Nandy, Yan Xu, 2019, Clinical and translational science.

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study

Dennis Liu, Jin-Sang Yoon, Gang Wang, 2017, Neuropsychiatric disease and treatment.

Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle

S. Gopal, M. Samtani, A. Russu, 2016, Journal of clinical psychopharmacology.

Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.

S. Gopal, B. Remmerie, A. Savitz, 2016, British journal of clinical pharmacology.

Design and conduct considerations for studies in patients with hepatic impairment

M. Chetty, M. Elmeliegy, P. Ravenstijn, 2022, Clinical and translational science.